Generic prices "twice as high" in Canada as in USA

7 September 2008

A report by the Fraser Institute, a Canadian think-tank, has found that senior citizens paid over twice as much for generic drugs as their US counterparts, due to opposite trends since 2003 in the two North American countries. However, branded drugs remain considerably cheaper for Canadians than for US residents.

The Fraser Institute report found that non-branded medicines cost 118% more in Canada versus the USA in 2006, up from 64% in 2003. The authors said that "high prices for generic drugs are caused by misguided public policies that shield retail pharmacies and generic drug manufacturers from the competitive market forces that would put downward pressure on the price of generic drugs."

Any gap in price is likely to have widened since 2006 as the price war between major retailers on low-cost drugs only started in that year (Marketletters passim). Some prescription drugs are now cheaper from Wal-Mart or Target, at $4 per month's supply, than the co-payment would be for an insured customer (Marketletter September 8).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight